Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial.

By K. Margolin, M. Ernstoff, O. Hamid, D. Lawrence, D. McDermott, I. Puzanov, J. Wolchok, Joseph I. Clark, M. Sznol, T. Logan and 5 more. The Lancet Oncology, 2012

1,045 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/2dbf0021d15e9ef1b74801fc82b9f9f96c9135d4

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. J. Joyce
2. D. Quail

In Oncology

1. J. Joyce
2. D. Quail
3. K. Flaherty
4. Georgina V. Long
5. R. Weinberg

Citations in the corpus

• Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. (2019, background): “Kinase inhibitors [46] and ipilimumab and/or anti-PD1 antibody therapy [47] can be safely used even in patients with symptomatic brain metastases, in fact it has shown significant efficacy in this area [48].”
• Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain (2018, neutral): “Increased blood bilirubin level 6 (6) 1 (1)”
• Melanoma Staging: Evidence-Based Changes in the American Joint Committee on Cancer Eighth Edition Cancer Staging Manual (2017, background): “as well as stratification and analysis, are often based on the presence/absence of CNS disease.(6-20,73,74) Therefore, this additional level of granularity in the M category “maps” bet-”
• The microenvironmental landscape of brain tumors (2017, background): “Comparison of results from these immunotherapy trials indicates that patients with brain metastases may respond similarly to patients with advanced cancer without brain metastases (i.e., patients with metastases in other organs) (Hodi et al., 2010; Margolin et al., 2012).”